MiRNA‐34c Suppresses Osteosarcoma Progression In Vivo by Targeting Notch and E2F. (9th April 2022)

• Record Type: Journal Article
• Authors: Bae, Yangjin; Zeng, Huan‐Chang; Chen, Yi‐Ting; Ketkar, Shamika; Munivez, Elda; Yu, Zhiyin; Gannon, Francis H.; Lee, Brendan H.
• Is Part Of: JBMR plus. Volume 6:Number 5(2022)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2022-04-09
• Subjects: E2F5 -- miRNA‐34c -- Notch -- Osteosarcoma -- Tumor suppressor; Bones -- Diseases -- Periodicals; Bones -- Metabolism -- Periodicals; Orthopedics -- Periodicals; 612.75104
• DOI: 10.1002/jbm4.10623
• Languages: English
• ISSNs: 2473-4039

Abstract

ABSTRACT: The expression of microRNAs (miRNAs) is dysregulated in many types of cancers including osteosarcoma (OS) due to genetic and epigenetic alterations. Among these, miR‐34c, an effector of tumor suppressor P53 and an upstream negative regulator of Notch signaling in osteoblast differentiation, is dysregulated in OS. Here, we demonstrated a tumor suppressive role of miR‐34c in OS progression using in vitro assays and in vivo genetic mouse models. We found that miR‐34c inhibits the proliferation and the invasion of metastatic OS cells, which resulted in reduction of the tumor burden and increased overall survival in an orthotopic xenograft model. Moreover, the osteoblast‐specific overexpression of miR‐34c increased survival in the osteoblast specific p53 mutant OS mouse model. We found that miR‐34c regulates the transcription of several genes in Notch signaling ( NOTCH1, JAG1, and HEY2 ) and in p53‐mediated cell cycle and apoptosis ( CCNE2, E2F5, E2F2, and HDAC1 ). More interestingly, we found that the metastatic‐free survival probability was increased among a patient cohort from Therapeutically Applicable Research to Generate Effective Treatments (TARGET) OS, which has lower expression of direct targets of miR‐34c that was identified in our transcriptome analysis, such as E2F5 and NOTCH1 . In conclusion, we demonstrate that miR‐34c is a tumor suppressive miRNA in OS progression in vivo . In addition, we highlight the therapeutic potential of targeting miR‐34c in OS. © 2022 The Authors. JBMR Plus published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research.